Class II Medical Device Licence Pathway

1. Key takeaways

Class II devices require an MDL before they may be imported or sold in Canada, and the application fee is 643 CAD (effective from 2026-04-01). The manufacturer must hold a valid MDSAP certificate. The dossier is organised around the description of the device, its intended use, quality management system evidence, and evidence of safety and effectiveness — and it is not required to reach the strength of clinical effectiveness evidence demanded for Class III and Class IV applications. This makes Class II the entry point into licensed territory for most manufacturers, and it also means the project budget is dominated not by the application fee but by the MDSAP certification that must sit underneath it.

• Class II devices require an MDL for import or sale; the application fee is 643 CAD from 2026-04-01.
• A valid MDSAP certificate is required from the manufacturer.
• The dossier covers device description, intended use, quality system evidence and safety and effectiveness evidence.
• Clinical effectiveness evidence at the Class III / IV strength is not required for Class II.
• The licence amendment fee is priced separately and must be budgeted alongside the initial application.

2. Legal basis

The table below lists the sources for the Class II pathway, including the current fee schedule, the validity requirement, the clinical evidence requirement from which the Class II position is inferred, the licence provisions of the Regulations, and the industry compilation on MDSAP.

3. Expert insights

Insight 1: The dividing line between Class II and Class III / IV lies in clinical effectiveness evidence.

Health Canada’s official position attaches the clinical effectiveness evidence requirement explicitly to Class III and IV. The Class II application fee tier (643 CAD) also sits far below Class III (14,163 CAD) and Class IV (30,713 CAD), and this gap reflects exactly the difference in review resources invested at each class. Read together, the two signals point in the same direction: Class II is assessed with a lighter evidentiary footprint, and a Class II dossier that borrows the full clinical-evidence architecture of a Class III filing is paying for structure the review does not require. The practical skill here is calibration — building the dossier to what the class actually demands.

Insight 2: Class II still requires an MDSAP certificate.

MDSAP is mandatory across Class II, III and IV (practical estimate: since 2019-01-01). This is the item most often underestimated in Class II project budgets and schedules — the cost and duration of MDSAP certification are frequently higher than the MDL application fee itself. A manufacturer that budgets only the government fee and assumes certification is a formality will discover that the audit occupies the critical path. Planning the certification audit early, and confirming that the audit scope covers Canada, removes the largest single scheduling risk in a Class II project.

Insight 3: The Class II amendment fee is priced separately.

Under Schedule 8 of the Order Respecting Fees for Drugs and Medical Devices and the Health Canada fee page, the Class II licence amendment application fee is 331 CAD (from 2026-04-01; in 2025 it was 325 CAD). Change management and the initial application should therefore be budgeted as separate line items. Licences are living authorisations, and modifications to an approved device or its manufacturer information are handled through the amendment route, with its own fee. A budget that contains only the initial application fee will understate the cost of the first planned change.

Insight 4: Class II covers a considerable range of common products.

Among Health Canada’s official examples, Class II includes electric toothbrushes and hearing aids; Class I includes bandages or adhesive bandages, crutches and canes, and manual toothbrushes; Class III includes hip implants and shoulder joint prostheses; Class IV includes artificial hearts. These examples are a useful calibration reference for classification judgements: the distance between a manual toothbrush and an electric one, both ordinary consumer objects, is the distance between Class I and Class II. When a product’s technical characteristics push it toward a boundary, the classification should be re-checked against Schedule 1 before the pathway is chosen.

4. Practical recommendations

• Build the budget in three segments: the 643 CAD application fee, the 331 CAD amendment fee, and the cost of MDSAP certification.
• Schedule MDSAP certification and the MDL application in parallel, not in series.
• Organise the dossier in four parts: device description, intended use, quality system evidence, and safety and effectiveness evidence.
• If the product’s technical characteristics place it near the Class III boundary, re-check the classification against Schedule 1 first, to avoid a pathway mismatch.
• Once the MDL is obtained, arrange the annual fee for the right to sell (460 CAD) and label compliance at the same time.

5. Verification checklist

• □ The classification has been confirmed as Class II and checked back against the Schedule 1 rules
• □ A valid MDSAP certificate is held, with Canada included in the audit scope
• □ The application fee (643 CAD) and the amendment fee (331 CAD) have been budgeted separately
• □ The four-part dossier structure is complete
• □ The annual fee for the right to sell (460 CAD) has been included in the annual cost base
• □ Labels have been brought into compliance with Sections 21–23

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Canadian market. Our team manages Health Canada Medical Device Licence and MDEL applications, prepares risk-classified dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com